News zum Sektor Gesundheit aus Neuseeland

 

Find insight on Bayer, Mega Lifesciences and Neuren Pharmaceuticals in the latest Market Talks covering Health Care....

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome. The post Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome appeared first on The Motley Fool Australia....

These shares are under pressure on Thursday. But why? The post Why Beach Energy, Elders, Maas, and Neuren shares are dropping today appeared first on The Motley Fool Australia....

Neuren shares FDA feedback on NNZ-2591 development plans in HIE and PTHS, with next steps and management insights. The post Neuren Pharmaceuticals shares FDA meeting feedback on NNZ-2591 clinical programs appeared first on The Motley Fool Australia....

With more than seven million users on the HotCopper forums, every discussion and speculation…...

Neuren Pharmaceuticals shares are paused from trading as investors await a further announcement from the company. The post Neuren Pharmaceuticals shares paused pending announcement appeared first on The Motley Fool Australia....

These shares are missing out on the good times on Tuesday. But why? The post Why Brainchip, Credit Corp, Graincorp, and Neuren shares are falling today appeared first on The Motley Fool Australia....

With more than seven million users on the HotCopper forums, every discussion and speculation…...

Company fueled by strong 2025 customer momentumAUSTIN, Texas--(BUSINESS WIRE)--Planview®, the leading platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced strong 2025 momentum, driven by significant customer growth, AI innovation, and industry recognition throughout the year. Additionally, Planview enters 2026 with new CEO Matt Zilli at the helm and an updated leadership team to accelerate its AI-first strategy. New Logo and Customer Momentum in 2025 Key customer wins and expansions across Financial Services, Insurance, Healthcare, Technology, Retail, and more have driven Planview's continued profitable growth. In 2025, the company added 274 net new customers; notable customers who selected or expanded their footprint with Planview in 2025 included: Currys Group, DHL, DTCC, EDF Renewables, Farmacia Guadalajara, Fisher & Paykel Healthcare, FIS, Garrett Motion, General Mills, Getinge Sterilization, Global Payments, Harman Connected Services, HCSC, Huntin...

Summerset Group reported record FY25 retirement village sales, up 26%, with strong growth in New Zealand and Australia. The post Summerset Group Holdings FY25 results: record sales and growth momentum appeared first on The Motley Fool Australia....

Neuren Pharmaceuticals has projected DAYBUE global net sales to hit US$700 million by 2028. The post Neuren Pharmaceuticals revises DAYBUE revenue projections to reach US$700 million in 2028 appeared first on The Motley Fool Australia....

These shares are having a good session on Wednesday. But why? The post Why EBR Systems, Endeavour, Monadelphous, and Neuren shares are racing higher today appeared first on The Motley Fool Australia....

These shares are starting the week with a bang. Here's why. The post Why 4DMedical, EOS, Gorilla Gold, and Neuren shares are racing higher today appeared first on The Motley Fool Australia....

The FDA has approved DAYBUE STIX, a new powder option for Rett syndrome that grows royalty streams. The post Neuren Pharmaceuticals wins DAYBUE STIX FDA approval appeared first on The Motley Fool Australia....

Find insight on Novo Nordisk, Ramsay Health Care and Fisher & Paykel in the latest Market Talks covering Health Care....

WELLINGTON (dpa-AFX) - Ryman Healthcare Ltd. (RYM.NZ), a retirement village and rest home operator, on Thursday reported loss in the first half compared with the previous year. For the half of the......

Find insight on Novo Nordisk, Ramsay Health Care and Fisher & Paykel in the latest Market Talks covering Health Care....

WELLINGTON (dpa-AFX) - Fisher & Paykel Healthcare Corp. Ltd. (FSPKF, FPH.AX), on Wednesday reported its profit increased in the first half of fiscal year 2025 compared with the previous year. For ......

The market's response was in appreciation of strong results and upgraded guidance The post Fisher & Paykel shares surge 8% on half-year results appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...